Recent News

• 04.25.2025 - Cogent Biosciences Presents Four Posters at the American Association for Cancer Research Annual Meeting 2025 and Announces Two New Leaders
• 03.25.2025 - Cogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting
• 03.12.2025 - Leerink's Global Healthcare Conference 2025
• 03.07.2025 - Cogent Biosciences Announces Participation in the Leerink Healthcare Conference
• 02.27.2025 - Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients
• 02.25.2025 - Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
• 02.10.2025 - Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2025 AAAAI Annual Meeting

Recent Filings

• 04.22.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.22.2025 - DEF 14A Other definitive proxy statements
• 04.22.2025 - ARS Annual Report to Security Holders
• 04.11.2025 - PRE 14A Other preliminary proxy statements
• 04.11.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 04.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.25.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 02.25.2025 - EX-99.1 EX-99.1
• 02.25.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.25.2025 - 8-K Current report